Doxorubin - PharmaKB

Doxorubin

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

2979 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Breast neoplasms	D001943	EFO_0003869	C50	105	428	201	18	83	769
Lymphoma	D008223	—	C85.9	108	337	128	15	36	558
Sarcoma	D012509	—	—	69	130	47	5	23	245
Large b-cell lymphoma diffuse	D016403	—	C83.3	54	157	53	3	10	241
Ovarian neoplasms	D010051	EFO_0003893	C56	73	109	68	1	16	235
Neoplasms	D009369	—	C80	105	73	16	1	8	177
Non-hodgkin lymphoma	D008228	—	C85.9	43	99	41	6	10	174
B-cell lymphoma	D016393	—	—	52	102	28	4	7	162
Carcinoma	D002277	—	C80.0	33	77	34	5	27	161
Liver neoplasms	D008113	EFO_1001513	C22.0	25	60	40	8	34	148

Show 38 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Triple negative breast neoplasms	D064726	—	—	24	95	20	—	9	136
Fallopian tube neoplasms	D005185	—	—	31	33	26	—	1	78
Stomach neoplasms	D013274	EFO_0003897	C16	10	33	11	—	9	57
Recurrence	D012008	—	—	19	30	9	—	6	56
Neuroblastoma	D009447	EFO_0000621	—	10	22	16	—	3	51
Osteosarcoma	D012516	—	—	13	23	11	—	8	48
Neoplasm metastasis	D009362	EFO_0009708	—	16	25	6	—	4	45
Endometrial neoplasms	D016889	EFO_0004230	—	6	20	20	—	—	44
Adenocarcinoma	D000230	—	—	9	24	9	—	3	40
Peritoneal neoplasms	D010534	—	—	11	15	7	—	6	36

Show 141 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Invasive hydatidiform mole	D002820	—	D39.2	2	12	—	—	—	14
Non-small-cell lung carcinoma	D002289	—	—	5	11	—	—	—	13
Syndrome	D013577	—	—	3	8	—	—	—	11
Glioblastoma	D005909	EFO_0000515	—	4	7	—	—	—	10
Cholangiocarcinoma	D018281	—	C22.1	4	6	—	—	2	10
Plasmablastic lymphoma	D000069293	—	C83.3	6	6	—	—	—	10
Hypersensitivity	D006967	EFO_0003785	T78.40	4	5	—	—	4	10
Adult t-cell leukemia-lymphoma	D015459	—	C91.5	4	6	—	—	—	9
Urologic neoplasms	D014571	—	C64-C68	4	6	—	—	—	8
Myelodysplastic syndromes	D009190	—	D46	6	4	—	—	—	8

Show 148 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Myelodysplastic-myeloproliferative diseases	D054437	—	—	4	—	—	—	—	4
Appendiceal neoplasms	D001063	EFO_0003880	C18.1	2	—	—	—	2	4
Cystadenocarcinoma	D003536	—	—	3	—	—	—	—	3
Skin neoplasms	D012878	EFO_0004198	C44	1	—	—	—	1	2
Sezary syndrome	D012751	—	C84.1	1	—	—	—	1	2
Pleural effusion	D010996	—	J90	1	—	—	—	1	2
Pleural neoplasms	D010997	—	—	1	—	—	—	1	2
Brenner tumor	D001948	—	—	2	—	—	—	—	2
Castration-resistant prostatic neoplasms	D064129	—	—	1	—	—	—	—	1
Primary myelofibrosis	D055728	—	D47.4	1	—	—	—	—	1

Show 16 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Cardiovascular diseases	D002318	EFO_0000319	I98	—	—	—	—	4	4
Pseudomyxoma peritonei	D011553	EFO_0007456	—	—	—	—	—	2	2
Inflammation	D007249	MP_0001845	—	—	—	—	—	2	2
Taste disorders	D013651	—	—	—	—	—	—	1	1
Dysgeusia	D004408	—	R43.2	—	—	—	—	1	1
Ageusia	D000370	EFO_1001758	—	—	—	—	—	1	1
Biliary tract neoplasms	D001661	—	C24.9	—	—	—	—	1	1
Fatigue	D005221	—	R53.83	—	—	—	—	1	1
Ataxia	D001259	—	R27.0	—	—	—	—	1	1
Ataxia telangiectasia	D001260	Orphanet_100	G11.3	—	—	—	—	1	1

Show 38 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	—
INN	—
Description	—
Classification	Unknown
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—